1036 related articles for article (PubMed ID: 23963734)
21. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L
Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344
[TBL] [Abstract][Full Text] [Related]
22. Conventional induction and post-remission therapy in APL: have we arrived?
Sanz MA; Iacoboni G; Montesinos P
Best Pract Res Clin Haematol; 2014 Mar; 27(1):33-8. PubMed ID: 24907015
[TBL] [Abstract][Full Text] [Related]
23. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
[TBL] [Abstract][Full Text] [Related]
25. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
[TBL] [Abstract][Full Text] [Related]
26. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Al Bahar S; Pandita R; Bavishi K; Kreze O
Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
[TBL] [Abstract][Full Text] [Related]
27. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
28. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Jaime-Pérez JC; González-Leal XJ; Pinzón-Uresti MA; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre H; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):816-9. PubMed ID: 26500134
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
30. Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
Lu Q; Chen Y; Li Z
Leuk Res; 2012 Jun; 36(6):e119-21. PubMed ID: 22386731
[No Abstract] [Full Text] [Related]
31. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
32. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
33. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
36. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
37. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
39. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
Eardley AM; Heller G; Warrell RP
Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987
[TBL] [Abstract][Full Text] [Related]
40. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
